NCT07259031

Brief Summary

This prospective clinical study aimed to evaluate the postoperative effects of temporary phrenic nerve paralysis induced by intraoperative phrenic nerve crush during lung resection surgery. The study compared postoperative pulmonary function, diaphragm activity, and clinical outcomes between patients who underwent intraoperative phrenic nerve crush and those who did not. The objective was to assess the reversibility, safety, and clinical impact of temporary phrenic nerve paralysis in relation to postoperative residual pleural space and prolonged air leak.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2019

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2023

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

November 17, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 2, 2025

Completed
Last Updated

December 2, 2025

Status Verified

November 1, 2025

Enrollment Period

3.6 years

First QC Date

November 17, 2025

Last Update Submit

November 21, 2025

Conditions

Keywords

residual air spaceprolonged air leakPhrenic nerve crushDiaphragm electromyography

Outcome Measures

Primary Outcomes (3)

  • Diaphragmatic Electromyography

    Quantitative assesment of diaphragmatic muscle activity using preoperative and postoperative EMG, recorded as motor unit action potential amplitude (mA) and duration (ms), to evaluate the degree of diaphragmatic dysfunction or recovery following intraoperative phrenic nerve compression.

    Preoperative; 3 weeks postoperative; 6 months postoperative

  • Pulmonary Function Test - FEV1

    Spirometric assessment of forced expiratory volume in 1 second (FEV1) to evaluate postoperative respiratory performance and the potential impact of brief intraoperative phrenic nerve compression. FEV1 values will be recorded as absolute volume (L) and as percent predicted (% predicted). Comparisons will be made between groups at each time point.

    Preoperative; 3 weeks postoperative; 6 months postoperative

  • Pulmonary Function Test - FVC

    Spirometric assessment of forced vital capacity (FVC) to evaluate postoperative respiratory performance and the potential impact of brief intraoperative phrenic nerve compression. FVC values will be recorded as absolute volume (L) and as percent predicted (% predicted). Comparisons will be made between groups at each time point.

    Preoperative; 3 weeks postoperative; 6 months postoperative

Secondary Outcomes (3)

  • Chest Tube Duration

    Up to postoperative day 30

  • Length of Hospital Stay

    Up to postoperative day 30

  • Prolonged Air Leak

    Up to postoperative day 30

Study Arms (2)

Phrenic crush

EXPERIMENTAL

Patients underwent standard lobectomy via muscle-sparing thoracotomy with brief intraoperative compression (1-2 seconds) of the phrenic nerve to induce transient diaphragmatic paralysis.

Procedure: İntraoperative phrenic nerve compression

Control

NO INTERVENTION

Patients underwent standard lobectomy via muscle-sparing thoracotomy without any intraoperative manipulation or compression of the phrenic nerve.

Interventions

Temporary intraoperative compression (1-2 seconds) of the phrenic nerve during lobectomy to induce transient diaphragmatic paralysis and minimize postoperative residual space.

Phrenic crush

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients (18+) who underwent lobectomy via muscle sparing thoracotomy
  • Patients with adequate preoperative pulmonary function to tolerate lobectomy
  • Patients who provided written informed consent for participation.
  • Patients with available postoperative follow-up data, including EMG and pulmonary function tests

You may not qualify if:

  • Patients who underwent wedge resection, segmentectomy, pneumonectomy, or VATS procedures
  • Patients with previous phrenic nerve injury, diaphragmatic paralysis, or neuromuscular disorders affecting respiratory muscles.
  • Patients with incomplete postoperative follow-up or missing EMG/PFT data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Konya City Hospital, Department of Thoracic Surgery

Konya, Konya, 42080, Turkey (Türkiye)

Location

Study Officials

  • Ferdane M Duran, MD

    University of Health Science, Konya City Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
This is an open-label study. Participants, surgeons, and outcome assessors are aware of group assignment.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study was designed as a parallel, two-arm interventional trial comparing patients undergoing lobectomy with or without brief intraoperative phrenic nerve compression. Participants were assigned to either the experimental group (phrenic nerve compression for 1-2 seconds) or the control group (no phrenic nerve manipulation). Postoperative respiratory function, diaphragmatic EMG findings, and clinical follow-up parameters were compared between the groups.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant professor of Thoracic Surgery

Study Record Dates

First Submitted

November 17, 2025

First Posted

December 2, 2025

Study Start

September 1, 2019

Primary Completion

March 31, 2023

Study Completion

June 30, 2023

Last Updated

December 2, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

İndividual participant data will not be shared because the study includes patient-specific clinical and electrophysiological data that cannot be fully anonymized. Data will only be used for the analysis described in the approved protocol.

Locations